Comparative Effectiveness of GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy

Affiliations

• ¹ Department of Ophthalmology, Mayo Clinic, Rochester, MN.
• ² Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
• ³ Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN; OptumLabs, Eden Prairie, MN.
• ⁴ Department of Public Health Sciences, University of Chicago, Chicago, IL.
• ⁵ Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
• ⁶ Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
• ⁷ Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Department of Health Policy and Management, Yale School of Public Health, New Haven, CT.
• ⁸ Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN.
• ⁹ OptumLabs, Eden Prairie, MN; Division of Endocrinology, Diabetes, & Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD; University of Maryland Institute for Health Computing, Bethesda, MD.